The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the BioShares Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its total assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering or product candidate ("lead drug") that has received U.S. Food and Drug Administration ("FDA") approval. The fund is non-diversified.
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.